

**To:** Lauren Zeise (Lauren.Zeise@oehha.ca.gov)[Lauren.Zeise@oehha.ca.gov]; LE CURIEUX Frank[Frank.LECURIEUX@echa.europa.eu]; Ross, Matthew[MRoss@cvm.msstate.edu]; Martin, Matt[Martin.Matt@epa.gov]  
**From:** Rusyn, Ivan  
**Sent:** Tue 2/10/2015 4:45:30 PM  
**Subject:** FW: IARC mono vol 112 section 4  
report (23).docx

Cancer in  
humans

exp

– Identify established and  
likely mechanistic events

Are there co  
the overa

Has each m  
suppressi  
of tumour

Are there alt  
(Uneven sup  
uneven re

– Determine whether each  
mechanism could  
operate in humans

Could differ  
humans and

**From:** Kathryn Guyton [mailto:GuytonK@iarc.fr]  
**Sent:** Tuesday, February 10, 2015 6:26 AM  
**To:** Rusyn, Ivan  
**Subject:** IARC mono vol 112 section 4

Bonjour Ivan!

In anticipation of the call today, kindly see the below the status of vol 112 Section 4 contributions. Matt Ross has completed everything, including a draft of 4.6 Mechanistic considerations for parathion! Others are in various states of completion. All submitted drafts have been sent for peer review.

Questions for you below, and let me know of anything else you'd like to discuss.

Thank you Ivan!!

Kate

Questions:

— Unless you would disagree, I wouldn't adjust assignments... nonetheless all drafts should be submitted/reviewed/revised within 2 weeks (24 Feb).

— what due date (suggest 24 Feb) and format do you want to use for Section 4.6? If you prefer a tabular summary of key evidence, this could be done in the Table Builder or using the attached Word file. Otherwise, we can propose one of the vol 110s as a model?

Le Curieux Frank

(4 /  
6)

DZN 4.2.1 Genetic and  
related effects  
(\*\*\*\*\*DIAZINON\*\*\*\*\*)  
(2015-01-13)  
GLYP 4.2.1 Genetic and  
related effects  
(\*\*\*\*\*GLYPHOSATE\*\*\*  
(2015-01-13)  
MAL 4.2.1 Genetic and  
related effects  
(\*\*\*\*\*MALATHION\*\*\*\*\*  
(2015-01-13)  
PAR 4.2.1 Genetic and  
related effects  
(\*\*\*\*\*PARATHION\*\*\*\*\*  
(2015-01-13)  
TCVP 4.6 Mechanistic  
considerations  
(\*\*\*\*\*TETRACHLOR\  
(2015-02-13)  
TCVP 4.2.1 Genetic and  
related effects  
(\*\*\*\*\*TETRACHLOR\  
(2015-01-13)

Ross Matthew K. (6 /  
6)

DZN 4.1. Toxicokinetic  
data  
(\*\*\*\*\*DIAZINON\*\*\*\*\*)  
(2015-01-13)  
GLYP 4.1. Toxicokinetic  
data  
(\*\*\*\*\*GLYPHOSATE\*\*  
(2015-01-13)  
MAL 4.1. Toxicokinetic  
data  
(\*\*\*\*\*MALATHION\*\*\*\*\*  
(2015-01-13)  
PAR 4.1. Toxicokinetic  
data  
(\*\*\*\*\*PARATHION\*\*\*\*\*  
(2015-01-13)  
PAR 4.6 Mechanistic  
considerations  
(\*\*\*\*\*PARATHION\*\*\*\*\*  
(2015-02-13)  
TCVP 4.1. Toxicokinetic  
data  
(\*\*\*\*\*TETRACHLOR  
(2015-01-13)

Zeise Lauren (12 /  
15)

DZN 4.2.4 Altered cell  
proliferation or death

(\*\*\*\*\*DIAZINON\*\*\*\*\*)  
 (2015-01-13)  
 DZN 4.2.2 Receptor-mediated effects  
 (\*\*\*\*\*DIAZINON\*\*\*\*\*)  
 (2015-01-13)  
 DZN 4.2.5 Other mechanisms  
 (\*\*\*\*\*DIAZINON\*\*\*\*\*)  
 (2015-01-13)  
 DZN 4.6 Mechanistic considerations  
 (\*\*\*\*\*DIAZINON\*\*\*\*\*)  
 (2015-02-13)  
 GLYP 4.2.2 Receptor-mediated effects  
 (\*\*\*\*\*GLYPHOSATE\*\*  
 (2015-01-13)  
 GLYP 4.2.4 Altered cell proliferation or death  
 (\*\*\*\*\*GLYPHOSATE\*\*  
 (2015-01-13)  
 GLYP 4.2.5 Other mechanisms  
 (\*\*\*\*\*GLYPHOSATE\*\*  
 (2015-01-13)  
 MAL 4.2.2 Receptor-mediated effects  
 (\*\*\*\*\*MALATHION\*\*\*\*\*  
 (2015-01-13)  
 MAL 4.2.5 Other mechanisms  
 (\*\*\*\*\*MALATHION\*\*\*\*\*  
 (2015-01-13)  
 MAL 4.2.4 Altered cell proliferation or death  
 (\*\*\*\*\*MALATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.2.2 Receptor-mediated effects  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.2.4 Altered cell proliferation or death  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.2.5 Other mechanisms  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 TCVP 4.2.2 Receptor-mediated effects  
 (\*\*\*\*\*TETRACHLOR  
 (2015-01-13)  
 TCVP 4.2.3 Other mechanisms

(\*\*\*\*\*TETRACHLOR

(2015-01-13)

Martin Matthew T. (1 /  
9)

DZN 4.3. Data relevant  
to comparisons across  
agents and endpoints

(\*\*\*\*\*DIAZINON\*\*\*\*\*

(2015-01-13)

DZN 4.5 Other adverse  
effects

(\*\*\*\*\*DIAZINON\*\*\*\*\*

(2014-11-18)

GLYP 4.3. Data  
relevant to comparisons  
across agents and  
endpoints

(\*\*\*\*\*GLYPHOSATE\*

(2015-01-13)

GLYP 4.5. Other  
adverse effects

(\*\*\*\*\*GLYPHOSATE\*

(2015-01-13)

MAL 4.3. Data relevant  
to comparisons across  
agents and endpoints

(\*\*\*\*\*MALATHION\*\*\*\*\*

(2015-01-13)

MAL 4.5. Other adverse  
effects

(\*\*\*\*\*MALATHION\*\*\*\*\*

(2015-01-13)

MAL 4.6 Mechanistic  
considerations

(\*\*\*\*\*MALATHION\*\*\*\*\*

(2015-02-13)

PAR 4.5. Other adverse  
effects

(\*\*\*\*\*PARATHION\*\*\*\*\*

(2015-01-13)

TCVP 4.5. Other  
adverse effects

(\*\*\*\*\*TETRACHLOF

(2015-01-13)

Rusyn Ivan (9 /  
12)

DZN 4.2.3 Oxidative  
stress, inflammation  
and  
immunosuppression

(\*\*\*\*\*DIAZINON\*\*\*\*\*

(2015-01-13)

DZN 4.4. Cancer

susceptibility data  
 (\*\*\*\*\*DIAZINON\*\*\*\*\*  
 (2015-01-13)  
 GLYP 4.4. Cancer  
 susceptibility data  
 (\*\*\*\*\*GLYPHOSATE\*  
 (2015-01-13)  
 GLYP 4.6 Mechanistic  
 considerations  
 (\*\*\*\*\*GLYPHOSATE\*  
 (2015-02-13)  
 GLYP 4.2.3 Oxidative  
 stress, inflammation  
 and  
 immunosuppression  
 (\*\*\*\*\*GLYPHOSATE\*  
 (2015-01-13)  
 MAL 4.2.3 Oxidative  
 stress, inflammation  
 and  
 immunosuppression  
 (\*\*\*\*\*MALATHION\*\*\*\*\*  
 (2015-01-13)  
 MAL 4.4. Cancer  
 susceptibility data  
 (\*\*\*\*\*MALATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.3. Data relevant  
 to comparisons across  
 agents and endpoints  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.4. Cancer  
 susceptibility data  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 PAR 4.2.3 Oxidative  
 stress, inflammation  
 and  
 immunosuppression  
 (\*\*\*\*\*PARATHION\*\*\*\*\*  
 (2015-01-13)  
 TCVP 4.3. Data  
 relevant to comparisons  
 across agents and  
 endpoints  
 (\*\*\*\*\*TETRACHLOF  
 (2015-01-13)  
 TCVP 4.4. Cancer  
 susceptibility data  
 (\*\*\*\*\*TETRACHLOF  
 (2015-01-13)